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Summary This study was undertaken to elucidate the mechanism(s) of differential sensitivity of human
bladder cancer cell lines J82 and SCaBER to mitomycin C (MMC) and its analogue, BMY 25067. The IC50
values for MMC and BMY 25067 in the SCaBER cell line were respectively 5- and 4-fold higher than in J82.
BMY 25282 and BMY 25067 were significantly more cytotoxic, on a molar basis, than MMC in both the cell
lines. NADPH cytochrome P450 reductase and DT diaphorase activities were significantly higher in the J82
cell line than in SCaBER, suggesting that relatively lower sensitivity of the SCaBER cell line to MMC and
BMY 25067 may be due to deficient drug activation. This conclusion was supported by the observation that
IC50 values for BMY 25282, which has lower quinone reduction potential than MMC and BMY 25067, did
not differ significantly in these cell lines. A correlation between drug sensitivity, oxyradical formation and
levels of antioxidative enzymes was not observed. These results suggest that the relatively lower sensitivity of
SCaBER cells to MMC or BMY 25067 may be independent of differential oxyradical formation. MMC-
induced DNA interstrand cross-link (ISC) formation was markedly lower in the SCaBER cell line than in J82.
However, it remains to be seen if the reduced ISC frequency in the SCaBER cell line is a consequence of
deficient drug activation or results from increased repair of the damaged DNA.
Mitomycin C (MMC) is widely used in the treatment of
various solid tumours, including human bladder carcinoma
(Crooke & Bradner, 1976; Carter, 1979). However, the fre-
quent occurrence of resistance to MMC limits its clinical
effectiveness (Moertel et al., 1968; Lenaz, 1985). Elucidation
of the biochemical mechanism(s) leading to MMC resistance
may, therefore, be essential for developing strategies to in-
crease the therapeutic value of this drug.
MMC requires enzymatic bioactivation, and metabolic
pathways for one- and two-electron reduction of MMC
leading to the generation of cytotoxic species have been
described (Iyer & Szybalski, 1963; Pan et al., 1984; Tomasz et
al., 1987; Siegel et al., 1992). While many enzymes have been
implicated in MMC bioactivation, NADPH cytochrome
P450 reductase and DT diaphorase appear to be the key
enzymes involved in its bioreductive activation (Keyes et al.,
1984; Pan et al., 1984; Hoban et al., 1990; Gustafson &
Pritsos, 1992; Siegel et al., 1992). Whereas the most abundant
lesion produced by enzymatically activated MMC is the
DNA monoadduct, MMC is believed to exert cytotoxic
activity primarily through the formation of DNA-DNA
cross-links (Long et al., 1984; Dorr et al., 1985; Tomasz et
al., 1987). MMC-dependent oxyradicals have also been pro-
posed to contribute to its cytotoxicity (Pan et al., 1984;
Pritsos & Sartorelli, 1986; Dusre et al., 1990).
Several independent investigators have shown that cellular
resistance to MMC often results from deficient drug activa-
tion due to the down-regulation of bioactivation enzymes
(Willson et al., 1985, 1987; Marshall et al., 1989; Hoban et
al., 1990; Pan et al., 1992). On the other hand, MMC resist-
ance in a subclone of the L1210 leukaemic cell line appears
to be due to reduced drug accumulation (Dorr et al., 1987).
Cross-resistance to MMC in a multidrug-resistant clone of
the MCF-7 human breast cancer cell line (ADR), selected for
resistance to doxorubicin, has been attributed to the reduced
formation of MMC-dependent oxyradicals (Dusre et al.,
1990).
Recent studies suggest that GSH/GST-mediated drug inac-
tivation may also play an important role in MMC resistance
(Perry et al., 1992; Siegel et al., 1992; Singh et al., 1992; Xu
& Singh, 1992a). We have shown that cross-resistance to
MMC in a multidrug-resistant variant of P388 mouse
leukaemia (P388/R-84) is independent of either deficient drug
activation or reduced drug accumulation, but seems to be
influenced by GSH/GST levels (Singh et al., 1992; Xu &
Singh, 1992a,b). Subsequently, using a panel of three
unrelated human bladder cancer cell lines (J82, HT-1197 and
SCaBER) differing in their sensitivities to MMC, we noticed
a good correlation between MMC cytotoxicity and GST
level, activity being highest in the relatively insensitive cell
line (SCaBER) and lowest in the comparatively sensitive cell
line, J82 (Xu et al., 1993). In addition, the results from this
study suggested that multiple mechanisms may be responsible
for the relatively lower sensitivity of SCaBER cells to MMC.
We have extended the study and compared other mechanisms
of MMC resistance, including the levels of bioactivation
enzymes, oxyradical formation, antioxidative enzyme levels
and MMC-induced DNA cross-link formation in J82 and
SCaBER cell lines, which are sensitive and relatively insen-
sitive, respectively, to MMC and its analogue, BMY
25067.
Materials and methods
Chemicals
MMC and its analogues were generously supplied by the
Bristol Myers Squibb Company. Sources of other chemicals
were as described previously (Xu & Singh, 1992a, b). Stock
solution of MMC was prepared in phosphate-buffered saline
(PBS), whereas MMC analogues BMY 25282 and BMY
25067 were dissolved in dimethylsulphoxide (DMSO). Fresh
drug solutions were prepared immediately before use. The
final concentration of DMSO was <0.5%, which did not
affect the colony-forming ability of either of the cell lines.
Cell lines
Human bladder cancer cells, J82 and SCaBER, were ob-
tained from the American Type Culture Collection (Rock-
ville, MD, USA). Monolayer cultures were maintained in
Eagle's minimum essential medium supplemented with non-
essential amino acids, sodium pyruvate, 10% fetal bovine
serum and antibiotics. The plating efficiencies of J82 and
SCaBER cells were 27 ± 5% and 45 ± 13% (n = 9) respec-
tively. The cell doubling times for J82 and SCaBER cell lines
were similar.
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Cell survival assay
The in vitro cytotoxicity of MMC and its analogues in
human bladder cancer cell lines was determined by colony
formation assay. Briefly, 3 x 103 cells were allowed to attach
overnight. The cells were exposed to different concentrations
of the drug for 1 h at 37°C. After washing the cells twice with
PBS, fresh medium was added and the flasks were incubated
for 8-10 days at 37°C in an atmosphere of 5% carbon
dioxide and 95% air. Colonies containing more than 50 cells
were counted under an inverted microscope. The IC50 value
(drug concentration producing 50% cell growth inhibition)
was determined by plotting percentage cell survival vs drug
concentration. Statistical significance was determined by
Student's t-test.
Enzyme assays
NADPH cytochrome P450 reductase activity was determined
by the procedure described by Hrycay et al. (1975). DT
diaphorase was measured according to the method described
by Ernster (1967) using 2,6-dichlorophenol indophenol
(DCPIP) as a substrate. The concentration of dicoumarol
used to study the inhibition of the reduction of DCPIP was
10 iM. GSH peroxidase and catalase activities were deter-
mined by the methods described by Beutler (1984). Protein
content was determined by the method of Bradford
(1976).
MMC-dependent lipidperoxidation
MMC-dependent oxyradical formation in J82 and SCaBER
cell lines was compared by monitoring the production of
2-thiobarbituric acid-reactive malondialdehyde (an indicator
of oxyradical formation). Malondialdehyde content was
determined according to the method described by Konings &
Drijver (1979) with slight modifications. The details of the
lipid peroxidation assay have been described by us previously
(Xu & Singh, 1992b).
Alkaline elution assay
Cells (0.5 x 106 in 5 ml of complete medium) were labelled
with [14C]thymidine (0.02 ItCi ml-'; specific activity,
56 mCi mmol-') for 48 h. The medium was removed and the
cells were washed twice with PBS. The radioactivity was
chased by a 24 h post-incubation at 37°C in fresh medium
containing 10 ZlM non-radioactive thymidine. The labelled
cells were incubated with different concentrations of MMC
for 1 h at 37°C, and washed twice with ice-cold PBS. Ali-
quots containing approximately 1 x 106 cells were irradiated
with 15 Gy of y-radiation on ice. DNA cross-link formation
was determined by using the alkaline elution technique as
described by Kohn et al. (1981). Interstrand cross-link (ISC)
frequency was calculated by using the equation:
ISC (Gy eq.) = ([(I-R0)/(1-R1)]1-I} x 15
where Ro and RI represent the fraction of DNA retained
from control and MMC-treated cells respectively.
Results
The in vitro cytotoxicity of MMC, BMY 25282 and BMY
25067 in J82 and SCaBER cell lines is shown in Figure 1.
The IC50 value for MMC in SCaBER cells (1.5 ± 0.15ILM)
was 5-fold higher (P<0.001) than in J82 (0.3 ± 0.04pM)
(Figure la). BMY 25282 and BMY 25067 appeared to be
significantly more cytotoxic, on a molar basis, than the
parent drug in both these cell lines (Figure lb and c). The
IC50 values for BMY 25282 in J82 and SCaBER cells were
0.026 ± 0.005 and 0.039 ± 0.012 gM, respectively, which did
not differ significantly (P = 0.14). Thus, BMY 25282 was
approximately 12- and 38-fold more cytotoxic than the
parent drug in J82 and SCaBER cells respectively. BMY
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Figure I Survival of cells exposed to various concentrations of
a, MMC; b, BMY 25282; and c, BMY 25067: (0) J82; (0)
SCaBER. Points represent mean ± s.d. of three independent
experiments.
25067 was 10- and 12.5-fold more active than MMC in J82
and SCaBER cells respectively. The IC50 values for BMY
25067 in J82 and SCaBER cells were 0.03 ± 0.001 and
0.12 ± 0.006 ILM respectively. The SCaBER cells displayed a
4-fold higher IC50 value for BMY 25067 (P<0.001) com-
pared with the J82 cells.
Table I shows the levels of key MMC bioactivation
enzymes in these cell lines. NADPH cytochrome P450 reduc-
tase activity in SCaBER cells was about 31% of that in the
J82 cell line. DT diaphorase activity was also significantly
lower in SCaBER cells than in J82.
Table II compares MMC-dependent lipid peroxidation (an
indicator of oxyradical formation) and the levels of cellular
antioxidative enzymes in these cells. MMC-dependent lipid
peroxidation was about 54% higher in the SCaBER cell line
than in J82 (P<0.005). Interestingly, the antioxidative
enzyme levels did not differ significantly between J82 and
SCaBER cell lines (Table II). We have shown previously that
the GSH level is also similar in J82 and SCaBER cell lines
(Xu et al., 1993).
Since cross-linking of DNA is believed to be important in
the cytotoxic activity of MMC (Long et al., 1984; Dorr et al.,
1985), ISC formation was compared in these cell lines (Figure
a
b
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Table I NADPH cytochrome P450 reductase and DT diaphorase activities in
14,000g supernatant fractions of J82 and SCaBER cells
NADPH cytochrome reductase DT diaphorase
Cell line (nmolmin- mg-' protein) (j.rol min- mg-' protein)
J82 26 ±5a 6 ± 2
SCaBER 8 ± 0.5b 0.5 ± 0.02C
aValues represent mean ± s.d. of three determinations. bSignificantly different
from J82, P <0.005, by t-test. cSignificantly different from J82, P <0.05, by t-test.
Table II MMC-dependent lipid peroxidation and GSH peroxidase
and catalase activities in J82 and SCaBER cells
Cell lines
J82 SCaBER
Lipid peroxidation 1.1 ± 0.05a 1.7 0.2b
(nmol h-' mg-' protein)
GSH peroxidase activityc 654 170 435 ± 110
(nmol minm-I mg ' protein)
Catalase activityd 3 ± 0.1 3 ± 0.4
(jLmol min- mg-' protein)
aValues represent mean ± s.d. of three determinations.
bSignificantly different from J82, P <0.005, by t-test. CGSH peroxi-
dase activity was measured using cumene hydroperoxide as a
substrate. dCatalase activity was measured by monitoring the decom-
position of hydrogen peroxide.
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Figure 2 DNA interstrand cross-links induced by different con-
centrations of MMC in J82 (0) and SCaBER (0) cell lines.
Each point represents mean ± s.d. of two independent elution
experiments.
2). MMC-induced ISC frequencies, at three drug concentra-
tions, were markedly lower in the SCaBER cell line than in
J82. The ISC frequencies induced by 0.75, 3.75 and 7.50 JAM
MMC in the SCaBER cell line were about 44%, 15% and
58%, respectively of those in J82 cells.
Discussion
Whereas several different mechanisms have been proposed to
account for MMC resistance (Dorr et al., 1987; Willson et
al., 1987; Marshall et al., 1989; Dusre et al., 1990; Singh et
al., 1992), deficient bioactivation of the drug appears to be
the most frequently encountered mechanism (Willson et al.,
1985; Hoban et al., 1990; Pan et al., 1992). This has led to
the synthesis of MMC analogues, such as BMY 25282, which
have much lower quinone reduction potential than the parent
drug (Doyle & Vyas, 1990). Thus, BMY 25282 has exhibited
superior anti-tumour activity in certain MMC-resistant cells
(for review see Doyle & Vyas, 1990). In the present study
also BMY 25282 appeared to be more active than MMC in
both the cell lines. These results suggest that BMY 25282
may be a superior anti-tumour agent to MMC. Unfor-
tunately, the toxicity of BMY 25282 has limited its clinical
use (Doyle & Vyas, 1990).
While the reduction potentials of BMY 25067 and MMC
are similar, this analogue has displayed much lower
haematological toxicity such as neutropenia than MMC in
preclinical studies (Bradner et al., 1990). Interestingly, both
the bladder cell lines examined in this study were significantly
more sensitive to BMY 25067 than MMC. Relatively higher
cytotoxicity of BMY 25067 compared with MMC has also
been reported in other cell lines (Dusre et al., 1990; Xu &
Singh, 1992a). Similarly, BMY 25067 exhibited superior
activity against B16 melanoma with a high percentage of
cures in mice when both the tumours and drugs were given
i.p. or in B16 melanoma implanted s.c. and BMY 25067
administered i.v. (Bradner et al., 1990). These results suggest
that BMY 25067 may be seriously considered for further
clinical development because of its superior cytotoxicity and
lower toxicity than the parent compound.
The cytotoxicity of MMC is suggested to be mediated by
DNA-DNA cross-linking and oxygen radical-mediated
damage (Dorr et al., 1985; Pritsos & Sartorelli, 1986; Dusre
et al., 1990). Although a good correlation has been reported
between MMC cytotoxicity and DNA cross-link formation
(Long et al., 1984; Dorr et al., 1985), the contribution of
oxyradicals in the activity of this agent is not as clear. Dusre
et al. (1990) have suggested that relatively lower sensitivity of
the MCF-7.ADR cell line to MMC, BMY 25282 and BMY
25067 compared with wild-type MCF-7 cells results from the
reduced oxygen radical formation. Previous studies from our
laboratory (Xu & Singh, 1992b) have also shown reduced
MMC-dependent oxyradical formation in P388/R-84 cells,
which are significantly cross-resistant to MMC, compared
with P388/S cells. Pritsos et al. (1986) suggested that,
although oxygen radicals do contribute to the aerobic
cytotoxicity of MMC and BMY 25282, the cytotoxic lesions
occur at site(s) other than DNA. However, McGurl and
Kennedy (1989) have concluded that oxyradicals may not
play a role in the anti-tumour activity of this drug. In this
study, sensitivity to MMC did not seem to correlate with
oxyradical formation. In fact, MMC-dependent lipid peroxi-
dation was significantly higher in MMC-resistant SCaBER
cells. Although the present study does not provide evidence
either for or against a role of oxyradicals in MMC cytotoxi-
city, this mechanism does not appear to contribute to the
differential sensitivity of J82 and SCaBER cells to MMC.
In the present study, the activities of two key MMC
bioactivation enzymes, NADPH cytochrome P450 reductase
and DT diaphorase, were significantly lower in SCaBER cells
than in J82 cells. These results suggest that the relatively
lower sensitivity of the SCaBER cell line to MMC and
perhaps BMY 25067 may be due to the deficient drug activa-
tion. The observation that the ICm values for BMY 25282 in
J82 and SCaBER cell lines did not differ significantly pro-
vides further support for this premise.
MMC has been shown to be preferentially cytotoxic to
hypoxic tumour cells (Kennedy et al., 1980; Rockwell, 1983).
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Several MMC-resistant cell lines, with deficient drug activa-
tion as mechanism of MMC resistance, have exhibited paren-
tal sensitivity to this agent under hypoxic conditions (Dul-
hanty et al., 1989; Marshall et al., 1989; Hoban et al., 1990).
Although the experiments described in the present study were
performed under aerobic conditions, it remains to be seen if
the sensitivity of the SCaBER cell line to MMC is similar to
that of J82 under hypoxic conditions.
The results of the present study suggest that, in addition to
the deficient bioactivation, reduced DNA cross-linking may
also contribute to the relatively lower sensitivity of SCaBER
cells to MMC. However, further studies are needed to deter-
mine whether reduced DNA cross-linking in the SCaBER cell
line is a consequence of deficient drug activation or results
from the increased repair of the damaged DNA in these
cells.
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Abbreviations: BMY 25282, 7-N-(dimethylaminomethylene)-
mitomycin C; BMY 25067, N-7-[2-(4-nitrophenyldithio)ethyl]-
mitomycin C; DCPIP, 2,6-dichlorophenol indophenol; GSH,
glutathione: GST, glutathione transferase; IC50, 50% inhibitory con-
centration; ISC, interstrand cross-link; MMC, mitomycin C; PBS,
phosphate-buffered saline.
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